GlassScriptPhysician profile
Christopher D Coccia
NPI 1083695696
$8,176.43
in general payments reported to CMS, 2019-2025
38 companies · $1,951 in 2025
The $1,951 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $942 · 2020: $840 · 2021: $925 · 2022: $1,091 · 2023: $1,116 · 2024: $1,312 · 2025: $1,951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,378.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,666.46 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $824.85 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $795.74 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $770.41 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $751.15 | 2019-2024 | Veozah, Myrbetriq |
| Lilly USA, LLC | $332.41 | 2021-2025 | Jardiance, Mounjaro, Kisunla |
| Abbvie INC. | $304.62 | 2021-2025 | Vraylar, Ubrelvy |
| Amgen INC. | $302.64 | 2019-2025 | Krystexxa, Evenity, Repatha |
| E.R. Squibb & Sons, L.L.C. | $271.57 | 2019-2024 | Eliquis |
| Janssen Pharmaceuticals, INC | $260.13 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $199.98 | 2019-2025 | |
| Exact Sciences Corporation | $182.16 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.39 | 2019-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $162.56 | 2022-2025 | |
| Dexcom, INC. | $144.19 | 2023-2025 | Dexcom G6 Transmitter |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Coccia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.